Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

Journal of Clinical Oncology, Vol 25, No 6 (February 20), 2007: pp. 634-641
© 2007 American Society of Clinical Oncology.
DOI: 10.1200/JCO.2006.06.3081

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kurian, A. W.
Right arrow Articles by Garber, A. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kurian, A. W.
Right arrow Articles by Garber, A. M.
Related Articles
Right arrowRelated Editorial
Right arrowRelated Correspondence
Right arrowRelated Article
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

A Cost-Effectiveness Analysis of Adjuvant Trastuzumab Regimens in Early HER2/neu–Positive Breast Cancer

Allison W. Kurian, Rebecca Newton Thompson, Allison F. Gaw, Sally Arai, Rafael Ortiz, Alan M. Garber

From the Department of Medicine, Division of Oncology; Department of Health Research and Policy, Division of Epidemiology; Department of Biological Sciences; Department of Medicine, Division of Bone Marrow Transplantation; Graduate School of Business; and the Veterans’ Affairs Palo Alto Health Care System and Center for Primary Care and Outcomes Research, Stanford University, Stanford, CA

Address reprint requests to Allison W. Kurian, MD, MSc, Division of Oncology, Stanford University School of Medicine, 875 Blake Wilbur Dr, Stanford, CA 94305-5820; e-mail: akurian{at}stanford.edu

PURPOSE: One-year adjuvant trastuzumab (AT) therapy, with or without anthracyclines, increases disease-free and overall survival in early-stage HER2/neu-positive breast cancer. We sought to evaluate the cost effectiveness of these regimens, which are expensive and potentially toxic.

METHODS: We used a Markov health-state transition model to simulate three adjuvant therapy options for a cohort of 49-year-old women with HER2/neu-positive early-stage breast cancer: conventional chemotherapy without trastuzumab; anthracycline-based AT regimens used in the National Surgical Adjuvant Breast and Bowel Project B-31 and North Central Cancer Treatment Group N9831 trials; and the nonanthracycline AT regimen used in the Breast Cancer International Research group 006 trial. The base case used treatment efficacy measures reported in the randomized clinical trials of AT. We measured health outcomes in quality-adjusted life-years (QALYs) and costs in 2005 United States dollars (US$) and subjected results to probabilistic sensitivity analysis.

RESULTS: In the base case, the anthracycline-based AT arm has an incremental cost-effectiveness ratio (ICER) of $39,982/QALY, whereas the nonanthracycline AT arm is more expensive and less effective; this result is insensitive to changes in recurrence rates, but if there is no benefit after 4 years, ICERs exceed $100,000/QALY for both AT arms. Results are moderately sensitive to variation in breast cancer survival rates and trastuzumab cost, and less sensitive to variations in cardiac toxicity.

CONCLUSION: AT has an ICER comparable to those for other widely used interventions. Longer clinical follow-up is warranted to evaluate the long-term efficacy and toxicity of different AT regimens.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?

Related Editorial

  • Do the Large Benefits Justify the Large Costs of Adjuvant Breast Cancer Trastuzumab?
    Bruce E. Hillner and Thomas J. Smith
    JCO 2007 25: 611-613 [Full Text]

Related Correspondence

  • Health Economics in the Journal of Clinical Oncology and an Evaluation of the Indirect Costs and Benefits Associated With Adjuvant Trastuzumab
    Gilberto de Lima Lopes, Jr and Stefan Gluck
    JCO 2007 25: 3382-3383 [Full Text]

Related Article

  • Health Economics in the Journal of Clinical Oncology and an Evaluation of the Indirect Costs and Benefits Associated With Adjuvant Trastuzumab
    Gilberto de Lima Lopes, Jr and Stefan Gluck
    JCO 2007 25: 3382-3383 [Full Text]


This article has been cited by other articles:


Home page
Cancer Res.Home page
D. Lesniak, Y. Xu, J. Deschenes, R. Lai, J. Thoms, D. Murray, S. Gosh, J. R. Mackey, S. Sabri, and B. Abdulkarim
{beta}1-Integrin Circumvents the Antiproliferative Effects of Trastuzumab in Human Epidermal Growth Factor Receptor-2-Positive Breast Cancer
Cancer Res., November 15, 2009; 69(22): 8620 - 8628.
[Abstract] [Full Text] [PDF]


Home page
The Annals of PharmacotherapyHome page
A. L. Chan, H. W. Leung, C.-L. Lu, and S. J. Lin
Cost-Effectiveness of Trastuzumab as Adjuvant Therapy for Early Breast Cancer: A Systematic Review
Ann. Pharmacother., February 1, 2009; 43(2): 296 - 303.
[Abstract] [Full Text] [PDF]


Home page
JAMAHome page
K. A. Phillips
Closing the Evidence Gap in the Use of Emerging Testing Technologies in Clinical Practice
JAMA, December 3, 2008; 300(21): 2542 - 2544.
[Full Text] [PDF]


Home page
CA Cancer J ClinHome page
Y.-C. T. Shih and M. T. Halpern
Economic Evaluations of Medical Care Interventions for Cancer Patients: How, Why, and What Does it Mean?
CA Cancer J Clin, July 1, 2008; 58(4): 231 - 244.
[Abstract] [Full Text] [PDF]


Home page
JRSMHome page
R. MacKenzie, S. Chapman, G. Salkeld, and S. Holding
Media influence on Herceptin subsidization in Australia: application of the rule of rescue?
J R Soc Med, June 1, 2008; 101(6): 305 - 312.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
M. Lidgren, B. Jonsson, C. Rehnberg, N. Willking, and J. Bergh
Cost-effectiveness of HER2 testing and 1-year adjuvant trastuzumab therapy for early breast cancer
Ann. Onc., March 1, 2008; 19(3): 487 - 495.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
G. de Lima Lopes Jr and S. Gluck
Health Economics in the Journal of Clinical Oncology and an Evaluation of the Indirect Costs and Benefits Associated With Adjuvant Trastuzumab
J. Clin. Oncol., August 1, 2007; 25(22): 3382 - 3383.
[Full Text] [PDF]


Home page
JCOHome page
N. J. Meropol and K. A. Schulman
In Reply
J. Clin. Oncol., August 1, 2007; 25(22): 3383 - 3383.
[Full Text] [PDF]


Home page
JCOHome page
B. E. Hillner and T. J. Smith
Do the Large Benefits Justify the Large Costs of Adjuvant Breast Cancer Trastuzumab?
J. Clin. Oncol., February 20, 2007; 25(6): 611 - 613.
[Full Text] [PDF]


Home page
JCOHome page
M. N. Levine, P. A. Ganz, and D. G. Haller
Economic Evaluation in the Journal of Clinical Oncology: Past, Present, and Future
J. Clin. Oncol., February 20, 2007; 25(6): 614 - 616.
[Full Text] [PDF]



About
JCO
 Editorial
Roster
 Advertising
Information
 Librarians &
Institutions
 Rights &
Permissions
 PDA Services

Copyright © 2007 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online